



Figure 4—figure supplement 3: Spartalizumab induces TNF- α secretion in uninfected and infected microspheres, which is neutralised by anti-TNF- α . PBMCs which were uninfected or infected with Mtb were encapsulated in alginate-collagen matrix after pre- incubation in Spartalizumab at 200 μ g/ml. The supernatant was collected to measure TNF- α secretion at day 7. (A) Spartalizumab induces TNF- α secretion in uninfected cells above background, which is accentuated with Mtb infection. (B) Anti-PD-1 antibody increases TNF- α secretion from Mtb infected cells above isotype, and the detectable levels are suppressed by anti-TNF antibody (50 μ g/ml).